Vision to transform current cancer supportive care treatment through patch technology.
ChemioCare is a pharmaceutical company working on a proprietary transdermal delivery platform.
Focused on improving quality of life and outcomes for patients undergoing cancer treatment, we believe that there is a significant opportunity to improve the profiles of generic medicines included in the standard of care by using transdermal technology.
Transdermal patches will address limitations with existing formulations by:
Eliminating peak blood levels
Reducing overall patient exposure to the medicine
Bypassing first pass metabolism
Improving patient compliance with a simplified, long-acting dosing regimen
The company is reformulating generic medicines that are well characterized and have a long and robust medical history. As result, ChemioCare will be able to leverage the 505(b)2 regulatory path, enabling:
a shortened development timeline,
and significantly reduced financial investment
Cancer Supportive Care Focus.
The company is using a lean development approach in a focused therapeutic area to maximize value creation opportunities. There is an exciting opportunity to expand into additional therapeutic areas after accelerating the supportive care products to market.
Led by strong Directors and Management with extensive scientific and industry experience.
At ChemioCare our goal is to have a positive impact on the lives of patients and families impacted by cancer by developing products that build on the current treatment paradigm safely and effectively.